In this context, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being proposed as potential drugs for managing cognitive disorders owing to their putative ability to affect neurobiological and metabolic pathways implicated in neurodegeneration.5 This evidence concerns the gene GLP1R and Cognitive impairment.